Meropenem Stada (Meropenem Anhydrous)

Meropenem exerts its antibacterial effect by binding to penicillin‑binding proteins on the bacterial cell wall, blocking the final step of peptidoglycan synthesis. This inhibition weakens the cell wall, causing osmotic rupture and bacterial death. Its structure also confers resistance to many β‑lactamases, giving it activity against a broad range of Gram‑positive, Gram‑negative and anaerobic pathogens.

The dosage of Meropenem Stada is individualized by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. No fixed regimen is provided here; healthcare professionals determine the appropriate dose and infusion rate for each patient.

Meropenem is classified as pregnancy category unknown, meaning that safety data are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus. Likewise, caution is advised during breastfeeding, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Meropenem Stada product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Meropenem shares the broad‑spectrum, β‑lactamase‑resistant profile of other carbapenems such as imipenem and ertapenem, but it offers a slightly wider activity against Pseudomonas aeruginosa and some resistant Enterobacteriaceae. Compared with non‑carbapenem β‑lactams, meropenem provides more reliable coverage for multidrug‑resistant organisms, though selection should be guided by susceptibility testing.

Meropenem Stada must be stored at 2‑8 °C (refrigerated). Keep the vials in the original packaging, protect them from light, and do not freeze or shake the solution. Once reconstituted, use the preparation within the time frame specified in the product labeling and maintain refrigeration if a longer storage period is required.

Meropenem Stada is administered as an intravenous infusion. The reconstituted solution is diluted in an appropriate compatible IV fluid and infused over a period usually ranging from 15 to 30 minutes, depending on the prescribed dose and patient condition. Administration should be performed by qualified healthcare personnel in a clinical setting.

The most serious adverse events include seizures, particularly in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis, which can cause life‑threatening diarrhea. Prompt recognition and medical intervention are essential if any of these events occur.

Meropenem Stada is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Patients with a history of severe allergic reactions to related drugs should avoid this medication. Additionally, caution is advised in patients with severe renal impairment, uncontrolled seizures, or pregnant and breastfeeding women unless the benefits clearly outweigh the risks.